irb

Study at IRB Barcelona shows early immunotherapy can eliminate these cells before they spread to other organs, preventing relapse

Investigation finds that genetic mutations could be detected decades before tumor appears

Barcelona Institute for Research in Biomedicine’s finding employs use of immunology against colon cancer and its metastasis

Doctor Joan Massagué has been appointed Scientific Director of the Sloan-Kettering Institute in New York , the world’s leading cancer research centre, which is part of the Memorial Sloan-Kettering Cancer Centre. The Catalan scientist has been chosen by an international expert committee and will take office on the 1^st of January 2014. The President and CEO of the Memorial Sloan-Kettering, Craig B. Thomson, said that Massagué had been given the job for his “exemplarity as a scientist” and because he is an “international leader” in the study of metastasis and factors regulating cell growth. This announcement follows last year’s appointment of another Catalan Doctor, Josep Baselga, as the Physician-in-Chief of the Memorial Sloan-Kettering Cancer Centre. Both Baselga and Massagué will continue to combine their responsibilities in New York with their research in Barcelona.

Through its FET-Flagship programme, the European Commission is allocating €1 billion to each of the two main research projects in Europe. The first one is a project to explore the properties of graphene, a new material deriving from graphite that might revolutionise industry as silicon did a few decades ago. The second one will simulate a human brain in order to understand how it exactly works. The Catalan Institute of Nanotechnology is one of the nine leading institutes coordinating the graphene project, in which 623 research groups from 32 different countries will participate. Furthermore, the Barcelona Supercomputing Center will take care of the calculations at a molecular level in the Human Brain Project.

Scientists from the Colorectal Cancer Laboratory at the Barcelona Institute of Biomedical Research (IRB) have discovered the essential process that allows colon cancer cells to metastasise. They have concluded that tumour cells need to form alliances with healthy cells in order to be able to colonise other organs. Tumour cells can survive in the transition period during the metastasis process thanks to a protein (interleukin-11), which is produced by healthy cells that are exposed to another protein (TGF-beta) present in the tumour’s microenvironment. This discovery may lead to new treatments and diagnostic proceedings for colon cancer patients. A test to predict relapse cases and target treatments is likely to be ready in 5 years. The study has been published by the prestigious journal Cancer Cell.